CN106659685B - 快速减轻帕金森病中的运动波动 - Google Patents

快速减轻帕金森病中的运动波动 Download PDF

Info

Publication number
CN106659685B
CN106659685B CN201480079968.6A CN201480079968A CN106659685B CN 106659685 B CN106659685 B CN 106659685B CN 201480079968 A CN201480079968 A CN 201480079968A CN 106659685 B CN106659685 B CN 106659685B
Authority
CN
China
Prior art keywords
levodopa
patient
administration
dose
fpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480079968.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659685A (zh
Inventor
R·P·巴泰奇
M·弗瑞德
M·M·利普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mertz Pharmaceutical Co ltd
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Priority to CN202110185196.6A priority Critical patent/CN113209055A/zh
Publication of CN106659685A publication Critical patent/CN106659685A/zh
Application granted granted Critical
Publication of CN106659685B publication Critical patent/CN106659685B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201480079968.6A 2014-04-21 2014-04-21 快速减轻帕金森病中的运动波动 Active CN106659685B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110185196.6A CN113209055A (zh) 2014-04-21 2014-04-21 快速减轻帕金森病中的运动波动

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110185196.6A Division CN113209055A (zh) 2014-04-21 2014-04-21 快速减轻帕金森病中的运动波动

Publications (2)

Publication Number Publication Date
CN106659685A CN106659685A (zh) 2017-05-10
CN106659685B true CN106659685B (zh) 2021-02-05

Family

ID=54332876

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110185196.6A Pending CN113209055A (zh) 2014-04-21 2014-04-21 快速减轻帕金森病中的运动波动
CN201480079968.6A Active CN106659685B (zh) 2014-04-21 2014-04-21 快速减轻帕金森病中的运动波动

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110185196.6A Pending CN113209055A (zh) 2014-04-21 2014-04-21 快速减轻帕金森病中的运动波动

Country Status (14)

Country Link
US (2) US20170296498A1 (enExample)
EP (2) EP3134077A4 (enExample)
JP (1) JP2017513866A (enExample)
KR (2) KR20170008754A (enExample)
CN (2) CN113209055A (enExample)
AU (2) AU2014391721B2 (enExample)
BR (1) BR112016024502A8 (enExample)
CA (1) CA2946165C (enExample)
IL (2) IL309959A (enExample)
MX (1) MX2016013741A (enExample)
RU (1) RU2698330C2 (enExample)
SG (1) SG11201608608PA (enExample)
WO (1) WO2015163840A1 (enExample)
ZA (1) ZA201607833B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
BR112020013749A2 (pt) * 2018-01-05 2020-12-01 Impel Neuropharma, Inc. dispensação intranasal de pó de levodopa por dispositivo olfativo de precisão
CN112955134A (zh) 2018-07-19 2021-06-11 英倍尔药业股份有限公司 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404276B2 (en) * 2002-03-20 2013-03-26 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
US20130287854A1 (en) * 2010-11-15 2013-10-31 Vectura Limited Compositions and uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
KR20110027817A (ko) * 2008-06-30 2011-03-16 노파르티스 아게 Ｍｇｌｕｒ 조절제를 포함하는 파킨슨병 치료용 조합물
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
MX2021014782A (es) * 2012-10-22 2023-03-23 Civitas Therapeutics Inc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404276B2 (en) * 2002-03-20 2013-03-26 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
US20130287854A1 (en) * 2010-11-15 2013-10-31 Vectura Limited Compositions and uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Rapid levodopa Augmentation following inhaled CVT-301 results in rapid improvement in motor response when administered to PD patients in the OFF state (S7,007);FREED,M等;<<Neurology>>;20140408;第82卷(第10期);摘要 *

Also Published As

Publication number Publication date
AU2014391721A1 (en) 2016-11-03
BR112016024502A2 (pt) 2017-08-15
CN106659685A (zh) 2017-05-10
IL248445A0 (en) 2016-12-29
CA2946165A1 (en) 2015-10-29
KR20170008754A (ko) 2017-01-24
RU2016144340A3 (enExample) 2018-05-22
CN113209055A (zh) 2021-08-06
EP3831375A1 (en) 2021-06-09
RU2016144340A (ru) 2018-05-22
MX2016013741A (es) 2017-04-06
BR112016024502A8 (pt) 2021-06-29
CA2946165C (en) 2022-10-18
US20230053976A1 (en) 2023-02-23
AU2020239754B2 (en) 2022-06-23
EP3134077A1 (en) 2017-03-01
KR20210144946A (ko) 2021-11-30
JP2017513866A (ja) 2017-06-01
US20170296498A1 (en) 2017-10-19
IL309959A (en) 2024-03-01
EP3134077A4 (en) 2017-12-20
SG11201608608PA (en) 2016-11-29
AU2020239754A1 (en) 2021-01-14
ZA201607833B (en) 2018-08-29
AU2014391721B2 (en) 2020-07-16
RU2698330C2 (ru) 2019-08-26
WO2015163840A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US12458615B2 (en) Methods for providing rapid relief of motor fluctuations in a Parkinson&#39;s disease patient
US20230053976A1 (en) Rapid relief of motor fluctuations in parkinson&#39;s disease
US9295661B2 (en) Methods for reducing inter-patient variability of levodopa plasma concentrations
JP2019108379A (ja) パーキンソン病の運動症状変動の迅速な緩和
HK40057047A (en) Rapid relief of motor fluctuations in parkinson&#39;s disease
HK40071377A (en) Levodopa formulations for rapid relief of parkinson’s disease
HK40023685A (en) Levodopa formulations for rapid relief of parkinson&#39;s disease
HK1217094B (en) Reducing inter-patient variability of levodopa plasma concentrations
HK1212258B (en) Levodopa formulations for rapid relief of parkinson&#39;s disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250206

Address after: 4th Floor, 6601 Liucha Road, Raleigh, North Carolina 27615, USA

Patentee after: Mertz Pharmaceutical Co.,Ltd.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: CIVITAS THERAPEUTICS, Inc.

Country or region before: U.S.A.